Astellas Announces Topline Results from Safety Study of Fezolinetant in Mainland China Clinical trial evaluated the safety and tolerability of 30 mg dose for the treatment of vasomotor symptoms (VMS) associated with menopause By Girl Power News , in News , at September 5, 2022